Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) – Suitable For Long Term Buy?
Currently, there are 257.70M common shares owned by the public and among those 256.81M shares have been available to trade. Insiders at the company have transacted a total of 198 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 11 of these insider trades were purchases, […]
